Hyperion does not invest in companies which develop, produce, transfer or stockpile controversial and nuclear weapons or their key components, nor does it invest in companies which produce tobacco or manufacture nicotine alternatives or tobacco-based products.

Hyperion applies environmental, social, and governance considerations when selecting, retaining or realising the investments of the Fund in addition to other methods in assessing company value. It does not have a fixed methodology or weightings for taking into account these ESG risks, and each investment opportunity is assessed on a case-by-case basis. Hyperion does not incorporate positive screening into its ESG investment process. 

The Fund Manager exercises stewardship through proxy voting and engagement. It engages with investee company management teams and boards to maintain a thorough understanding of material issues. In relation to ESG factors, Hyperion prioritises issues with the greatest materiality to financial and/or operating performance, issues with systemic influence (such as climate change), and adequacy of public disclosure on ESG factors/performance.

Hyperion has been a signatory to the UN Principles of Responsible Investing since February 2009 and an official supporter of the Task Force on Climate-Related Financial Disclosures (TCFD) since November 2019.